09/523,455

(FILE 'HOME' ENTERED AT 11:29:51 ON 11 APR 2001)

FILE 'USPATFULL' ENTERED AT 11:30:01 ON 11 APR 2001

L1 28 S CETRORELIX
L2 12 S L1/CLM
L3 3 S TEVERELIX
L4 56 S ANTIDE
L5 10 S L4/CLM
L6 1 S ABARELIX

FILE 'PCTFULL' ENTERED AT 11:52:39 ON 11 APR 2001

L7 14 S L6
L8 4 S L7/CLM

FILE 'EUROPATFULL, MEDLINE, EMBASE' ENTERED AT 11:56:26 ON 11 APR 2001

L9 24 S L6

FILE 'STNGUIDE' ENTERED AT 11:59:55 ON 11 APR 2001

FILE 'MEDLINE, EMBASE' ENTERED AT 12:02:59 ON 11 APR 2001

FILE 'STNGUIDE' ENTERED AT 12:02:59 ON 11 APR 2001

FILE 'MEDLINE, EMBASE' ENTERED AT 12:03:28 ON 11 APR 2001

FILE 'STNGUIDE' ENTERED AT 12:03:30 ON 11 APR 2001

FILE 'MEDLINE, EMBASE' ENTERED AT 12:08:51 ON 11 APR 2001

FILE 'STNGUIDE' ENTERED AT 12:08:55 ON 11 APR 2001

FILE 'MEDLINE, EMBASE' ENTERED AT 12:09:36 ON 11 APR 2001

FILE 'STNGUIDE' ENTERED AT 12:09:36 ON 11 APR 2001

FILE 'MEDLINE, EMBASE' ENTERED AT 12:10:14 ON 11 APR 2001

FILE 'STNGUIDE' ENTERED AT 12:10:18 ON 11 APR 2001

FILE 'USPATFULL' ENTERED AT 12:13:28 ON 11 APR 2001

L10 10 S (PROGESTOGEN#(S)ETHINYLESTRADIOL)
L11 29 S PROGESTOGEN#(S)MESTRANOL
L12 2 S L11/CLM
L13 20 S L11(L)CONTRACEPT?
L14 25 S CLOMIPHENE(S)GONADOTROPIN#
L15 25 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib ncl 10-15

L1 ANSWER 10 OF 28 USPATFULL
ACCESSION NUMBER: 2000:15636 USPATFULL
TITLE: Immobilized and activity-stabilized complexes of LHRH antagonists and processes for their preparation
INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Deger, Wolfgang, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
Losse, Gunter, Dresden, Germany, Federal Republic of
Naumann, Wolfgang, Zug, Germany, Federal Republic of
Murgas, Sandra, Dresden, Germany, Federal Republic of
PATENT ASSIGNEE(S): Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6022860	20000208
APPLICATION INFO.:	US 1998-48244	19980326 (9)
PRIORITY INFORMATION:	DE 1997-19712718	19970326

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Moezie, F. T.
LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/015.000
NCLS: 424/198.100; 514/012.000; 514/841.000; 514/951.000; 530/328.000; 530/331.000

L1 ANSWER 11 OF 28 USPATFULL
ACCESSION NUMBER: 2000:4808 USPATFULL
TITLE: Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
INVENTOR(S): Roder, Hanno, Ratingen, Germany, Federal Republic of
Lowinger, Timothy B., Nishinomiya, Japan
Brittelli, David R., Branford, CT, United States
VanZandt, Michael C., Guilford, CT, United States
PATENT ASSIGNEE(S): Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6013646	20000111
APPLICATION INFO.:	US 1998-109131	19980702 (9)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/219.000
NCLS: 540/556.000

L1 ANSWER 12 OF 28 USPATFULL
ACCESSION NUMBER: 1999:159993 USPATFULL
TITLE: Means for treating prostate cancer
INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt/Main, Germany, Federal Republic of
Riethmuller-Winzen, Hilde, Frankfurt/Main, Germany, Federal Republic of
Rawert, Jurgen, Alzenau, Germany, Federal Republic of
PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5998377	19991207
APPLICATION INFO.:	US 1998-57458	19980409 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-908198, filed on 7 Aug 1997
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/015.000
NCLS: 514/284.000

L1 ANSWER 13 OF 28 USPATFULL
ACCESSION NUMBER: 1999:146533 USPATFULL
TITLE: Nova- and decapeptides in the preparation of a drug for the treatment of aids
INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Kutscher, Bernhard, Maintal, Germany, Federal Republic of
Bernd, Michael, Frankfurt am Main, Germany, Federal Republic of
Niemeyer, Ulf, Offenbach, Germany, Federal Republic of
PATENT ASSIGNEE(S): ASTA Medica AG, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5985834	19991116
	WO 9500168	19950105
APPLICATION INFO.:	US 1995-569111	19951218 (8)

WO 1994-EP1037 19940402
19951218 PCT 371 date
19951218 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1993-4320201	19930618

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Tsang, Cecilla J.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/015.000
NCLS: 514/800.000; 530/313.000; 530/328.000; 930/130.000

L1 ANSWER 14 OF 28 USPATFULL
ACCESSION NUMBER: 1999:128511 USPATFULL
TITLE: Pharmaceutical formulations for sustained drug delivery
INVENTOR(S): Gefter, Malcolm L., Lincoln, MA, United States
Barker, Nicholas, Southborough, MA, United States
Musso, Gary, Hopkinton, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5968895	19991019	
APPLICATION INFO.:	US 1996-762747	19961211	(8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP; Mandragouras, Amy E.; DeConti, Giulio A.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 10
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/002.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/800.000; 530/313.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000

L1 ANSWER 15 OF 28 USPATFULL
ACCESSION NUMBER: 1999:110309 USPATFULL
TITLE: Androgenic steroid compounds and a method of making and using the same
INVENTOR(S): Cook, C. Edgar, Staunton, VA, United States

Kepler, John A., Raleigh, NC, United States
Lee, Yue-Wei, Chapel Hill, NC, United States
Wani, Mansukh C., Durham, NC, United States
PATENT ASSIGNEE(S): Research Triangle Institute, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5952319	19990914
APPLICATION INFO.:	US 1997-979369	19971126 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Badio, Barbara
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 1048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 514/179.000
NCLS: 514/171.000; 514/182.000; 552/515.000; 552/526.000; 552/539.000; 552/632.000; 552/639.000; 552/641.000

L2 ANSWER 11 OF 12 USPATFULL

ACCESSION NUMBER: 97:78416 USPATFULL

TITLE: Products for administering an initial high dose of Cetrorelix and producing a combination package for use when treating diseases

INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of

PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5663145	19970902	
APPLICATION INFO.:	US 1994-354838	19941208	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1993-4342091	19931209

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Russel, Jeffrey E.

LEGAL REPRESENTATIVE: Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 7

LINE COUNT: 227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NCL NCLM: 514/015.000
NCLS: 514/800.000

=> d ibib ncl abs 10-11

L2 ANSWER 10 OF 12 USPATFULL
ACCESSION NUMBER: 1998:75185 USPATFULL
TITLE: Long-acting injection suspensions and a process for their preparation
INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Klokkers-Bethke, Karin, Lenggries, Germany, Federal Republic of
Reissman, Thomas, Frankfurt, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
PATENT ASSIGNEE(S): Asta Medica Aktiengellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5773032	19980630
APPLICATION INFO.:	US 1996-661017	19960610 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 424/501.000
NCLS: 424/502.000
AB Poorly soluble salts of LHRH analogues, for example cetrorelix embonate, display an intrinsic sustained release effect in the grain size 5 .mu.m to 200 .mu.m.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 12 USPATFULL
ACCESSION NUMBER: 97:78416 USPATFULL
TITLE: Products for administering an initial high dose of Cetrorelix and producing a combination package for use when treating diseases
INVENTOR(S): Engel, Jurgen, Alzenau, Germany, Federal Republic of
Hilgard, Peter, Frankfurt, Germany, Federal Republic of
Reissmann, Thomas, Frankfurt, Germany, Federal Republic of
PATENT ASSIGNEE(S): ASTA Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5663145	19970902
APPLICATION INFO.:	US 1994-354838	19941208 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1993-4342091	19931209
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE: &	Cushman Darby & Cushman IP Group of Pillsbury Madison Sutro LLP	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	7	
LINE COUNT:	227	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NCL NCLM: 514/015.000
NCLS: 514/800.000

AB For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 ibib ncl abs kwic 1-3

L3 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 2000:167538 USPATFULL
TITLE: Implants containing bioactive peptides
INVENTOR(S): Deghenghi, Romano, Cheseaux Dessus B1, St. Cergue, Switzerland

	NUMBER	DATE
PATENT INFORMATION:	US 6159490	20001212
APPLICATION INFO.:	US 2000-543707	20000405 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-311744, filed on 14 May 1999, now patented, Pat. No. US 6077523 which is a division of Ser. No. US 1997-897942, filed on 21 Jul 1997, now patented, Pat. No. US 5945128

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25444	19960904 (60)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NCL NCLM: 424/426.000
NCLS: 264/004.100; 424/501.000; 424/502.000
AB A pharmaceutical implant for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months. This implant has a diameter of about 1 to 2 mm, a length of between about 10 and 25 mm and is obtainable from a process which includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; sterilizing the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and sterilized copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting a cylindrical rod from the extruded mixture to form the pharmaceutical implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . an LHRH agonist or antagonist, such as a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix,** ramorelix, antide, nictide, azaline B, azaline C or ganirelix.
DETD . . . required by the individual LHRH analog, rods containing 22 mg of leuprolide, 10 mg of goserelin and 30 mg of **teverelix** were

similarly obtained.

CLM What is claimed:

. . . the bioactive peptide or peptide analog is a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix,** ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

L3 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER:	2000:77041 USPATFULL	
TITLE:	Process to manufacture implants containing bioactive peptides	
INVENTOR(S):	Deghenghi, Romano, Cheseaux Dessus B1, St. Cergue, Switzerland	
	NUMBER	DATE
PATENT INFORMATION:	US 6077523	20000620
APPLICATION INFO.:	US 1999-311744	19990514 (9)
RELATED APPLN. INFO.:	Division of Ser. No. ~~US 1997-897942~~, filed on 21 Jul 1997, now patented, Pat. No. US 5945128	
	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25444	19960904 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Azpuru, Carlos A.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	353	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NCL NCLM: 424/426.000
NCLS: 264/004.100; 424/501.000; 424/502.000

AB A pharmaceutical implant for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months. This implant has a diameter of about 1 to 2 mm, a length of between about 10 and 25 mm and is obtainable from a process which includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; sterilizing the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and sterilized copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting a cylindrical rod from the extruded mixture to form the pharmaceutical implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . an LHRH agonist or antagonist, such as a pharmaceutically

acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix**, ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

DETD . . . required by the individual LHRH analog, rods containing 22 mg of leuprolide, 10 mg of goserelin and 30 mg of **teverelix** were similarly obtained.

CLM What is claimed is:

. . . the bioactive peptide or peptide analog is a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix**, ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

. . . the bioactive peptide or peptide analog is a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix**, ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

L3 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 1999:102518 USPATFULL

TITLE: Process to manufacture implants containing bioactive peptides

INVENTOR(S): Deghenghi, Romano, Cheseaux Dessus B1, St. Cergue, Switzerland

	NUMBER	DATE	
PATENT INFORMATION:	US 5945128	19990831	
APPLICATION INFO.:	US 1997-897942	19970721	(8)
PRIORITY INFORMATION:	US 1996-25449	19960904	(60)

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Azpuru, Carlos A.

LEGAL REPRESENTATIVE: Pennie & Edmonds LLP

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NCL NCLM: 424/501.000
NCLS: 264/004.100; 424/502.000

AB A process for manufacturing a pharmaceutical composition for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 months. This process includes the steps of grinding a copolymer of lactic acid and glycolic acid having a ratio of glycolide to lactide units of from about 0 to 5:1 to a particle size of between about 50 and 150 .mu.m; sterilizing the ground copolymer with a dose of between about 1 and 2.5 Mrads of ionizing .gamma.-radiation; wetting the ground and sterilized copolymer with a sterile aqueous slurry of a bioactive peptide or peptide analog; aseptically blending the copolymer and the slurry to obtain a homogeneous mixture of the copolymer and between about 10 and 50% of the bioactive peptide or peptide analog; drying the mixture at reduced pressure and at temperature not exceeding 25.degree. C.; aseptically extruding the dried

mixture at a temperature between about 70 and 110.degree. C.; and aseptically cutting cylindrical rods of about 1 to 2 mm diameter and between about 10 and 25 mm in length from the extruded mixture to form the pharmaceutical implants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . an LHRH agonist or antagonist, such as a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix**, ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

DETD . . . required by the individual LHRH analog, rods containing 22 mg of leuprolide, 10 mg of goserelin and 30 mg of **teverelix** were similarly obtained.

CLM What is claimed is:

. . . the bioactive peptide or peptide analog is a pharmaceutically acceptable salt of leuprolide, goserelin, triptorelin, buserelin, avorelin, deslorelin, histrelin, cetrorelix, **teverelix**, ramorelix, antide, nictide, azaline B, azaline C or ganirelix.

L5 ANSWER 10 OF 10 USPATFULL
ACCESSION NUMBER: 93:5372 USPATFULL
TITLE: Combined treatment with GnRH antagonist and GnRH to control gonadotropin levels in mammals
INVENTOR(S): Hodgen, Gary D., Norfolk, VA, United States
PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Netherlands (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5180711	19930119
APPLICATION INFO.:	US 1990-538375	19900614 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lee, Lester L.
ASSISTANT EXAMINER: Marshall, S. G.
LEGAL REPRESENTATIVE: Ostrolenk, Faber, Gerb & Soffen
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 383
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ncl 10

L5 ANSWER 10 OF 10 USPATFULL
NCL NCLM: 514/015.000
NCLS: 530/328.000

=> d kwic l5 10

L5 ANSWER 10 OF 10 USPATFULL
CLM What is claimed is:
8. A method according to claim 6 wherein said GnRH antagonist is **Antide**.

18. A method according to claim 17 wherein said GnRH antagonist is **Antide**.

L10 ANSWER 8 OF 10 USPATFULL
ACCESSION NUMBER: 85:43142 USPATFULL
TITLE: Triphasic oral contraceptive
INVENTOR(S): Pasquale, Samuel A., Basking Ridge, NJ, United States
PATENT ASSIGNEE(S): Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 4530839	19850723	
APPLICATION INFO.:	US 1983-536135	19830926	(6)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Lambert, Benjamin F.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CLM What is claimed is:

1. A method of contraception which comprises administering for 21 successive days to a female of childbearing age a combination of an estrogen and a **progestogen** in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-**ethinylestradiol** and in progestogenic activity to 0.125-0.75 mg of norethindrone for 7 days; for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17.alpha.-**ethinylestradiol** and in progestogenic activity to 0.50-1.0 mg of norethindrone; and for the next 7 days an estrogen daily dosage equal to 0.02-0.05 mg of 17.alpha.-**ethinylestradiol** and in progestogenic activity of 0.75-2.0 mg of norethindrone; followed by 7 days without estrogen and progestrogen administration, provided that.

. .

6. The method of claim 1 wherein the estrogen is 17.alpha.-**ethinylestradiol** and the **progestogen** is norethindrone.

7. The method of claim 1 wherein the estrogen is 17.alpha.-**ethinylestradiol** and the **progestogen** is D-17.beta.-acetoxy-13.beta.-ethyl-17.alpha.-ethinyl-gon-4-en-3-one oxime.

. . . method of claim 1 which comprises administering for 21 successive days to a female of childbearing age a combination of 17.alpha.-**ethinylestradiol** and norethindrone in a contraceptively effective daily dosage corresponding to 0.035 mg of 17.alpha.-**ethinylestradiol** and 0.50 mg of norethindrone for 7 days; for the next 7 days a daily dosage equal to 0.035 mg of 17.alpha.-**ethinylestradiol** and 0.75 mg of norethindrone; and for the next 7 days a daily dosge equal to 0.035 mg of 17.alpha.-**ethinylestradiol** and 1.0 mg of norethindrone; followed by 7 days without estrogen and **progestogen** administration.

L10 ANSWER 9 OF 10 USPATFULL
ACCESSION NUMBER: 76:39442 USPATFULL
TITLE: Method for contraception by the administration of

sequential contraceptive preparations

INVENTOR(S): Lachnit-Fixson, Ursula, Berlin, Germany, Federal Republic of

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berin & Bergkamen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3969502	19760713
APPLICATION INFO.:	US 1974-486757	19740709 (5)
DISCLAIMER DATE:	19930217	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1973-350590, filed on 12 Apr 1973, now patented, Pat. No. US 3939264	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2218831	19720414
	DE 1973-2310963	19730303
	DE 1973-2335265	19730709

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: Millen, Raptes & White
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM It is also possible, for example, to utilize, in one stage, the **progestogen** in combination with an estrogen derived from 17.alpha.-**ethinylestradiol**. These compounds generally have a lesser gastric compatibility and a stronger effect on the carbohydrate and fat metabolism. In the other stage, the **progestogen** can then be used in combination with an estrogen derived from the natural estrogen and which does not have the. . .

SUMM . . . different estrogens are used in the first and second stages, preferred embodiment is to utilize, in the first stage, the **progestogen** in combination with a 17.alpha.-**ethinylestradiol** derivative and, in the second stage, the **progestogen** in combination with an estrogen which does not contain a 17.alpha.-ethinyl group.

CLM What is claimed is:

7. A contraceptive composition according to claim 5 wherein in the first stage, the estrogen is 0.030 mg. of 17.alpha.-**ethinylestradiol** and the **progestogen** is 0.050 mg. of d-norgestrel per unit dosage and, in the second state, 0.040 mg. of 17.alpha.-**ethinylestradiol** and 0.125 mg. of d-norgestrel per unit dosage.

8. A contraceptive composition according to claim 5 wherein, in the first stage, the estrogen is 0.030 mg. of 17.alpha.-**ethinylestradiol** and the **progestogen** is 1 mg. of 17.alpha.-ethinyl-19-nortestosterone acetate per unit dosage and, in the second stage, 0.050 mg. of 17.alpha.-**ethinylestradiol** and 2 mg. of 17.alpha.-ethinyl-19-nortestosterone acetate per unit dosage.

L10 ANSWER 10 OF 10 USPATFULL
ACCESSION NUMBER: 76:27850 USPATFULL

TITLE:	Method for contraception by the application of combination-type sequential preparations
INVENTOR(S):	Lachnit-Fixson, Ursula, Berlin, Germany, Federal Republic of Pitchford, Alan G., High Hurstwood, near Uckfield, England
PATENT ASSIGNEE(S):	Schering Aktiengesellschaft, Berlin & Bergkamen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 3957982	19760518	
APPLICATION INFO.:	US 1974-535575	19741223	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1973-2365103	19731221

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Millen, Raptes & White
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1
LINE COUNT:	397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD It is also possible, for example, to employ, in one stage, a **progestogen** in combination with an estrogen derived from 17.alpha.-**ethinylestradiol**. These estrogens generally have a lessor gastric compatibility and exert a stronger effect on carbohydrate and fat metabolism. In one of the other stages, the **progestogen** can then be utilized in combination with an estrogen derived from a natural estrogen lacking the above-described side-effects.

CLM What is claimed is:

. . . which comprises administering for 21 successive days to a female of child-bearing age a combination of an estrogen and a **progestogen**, for the first 4-6 days in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.020-0.050 mg. of 17.alpha.-**ethinylestradiol** and in progestogenic activity to 0.050-0.125 mg. of d-norgestrel; for the next 4-6 days, at an estrogen daily dosage from 1-2 times the initial daily low dosage and at a **progestogen** daily dosage of from 1-1.5 times the dosage of the first 4-6 days; and for the next 9-11 days, at a daily estrogen dosage of from the initial daily dosage to the subsequent daily dosage and at a **progestogen** daily dosage higher than the previous daily dosages of up to 3 times that of the first daily dosage and corresponding in progestogenic activity to 0.100-0.250 mg. of d-norgestrel, followed by about 7 days without **progestogen** and estrogen administration.

L13 ANSWER 17 OF 20 USPATFULL
ACCESSION NUMBER: 77:16958 USPATFULL
TITLE: Contraceptive polypeptides
INVENTOR(S): Kent, Jr., Harry A., Athens, GA, United States
PATENT ASSIGNEE(S): Research Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4016259	19770405
APPLICATION INFO.:	US 1975-580235	19750523 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1974-492179, filed on 26 Jul 1974, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Gotts, Lewis
ASSISTANT EXAMINER: Suyat, Reginald J.
LEGAL REPRESENTATIVE: Cooper, Dunham, Clark, Griffin & Moran
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 10
LINE COUNT: 565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . acids as well as their pharmacologically acceptable derivatives and salts. These compounds are useful both orally and parenterally as mammalian **contraceptives**.

SUMM The principal class of compounds now utilized as **contraceptives** for animals, including humans, are steroidal in nature. The most widely employed agents are combinations of **progestogens** such as norethindrone and ethynodiol with estrogens such as ethynyl estradiol and **mestranol**. The use of such oral **contraceptives** is associated with a certain degree of well recognized risk. The principal risk is the occurrence of thromboembolism, although other. . .

SUMM Accordingly, the art has long been interested in finding suitable substitutes for steroidal **contraceptives**.

SUMM . . . progravid hamsters. This tetrapeptide, and certain related peptides, derivatives and salts, when administered orally or parenterally to animals, are useful **contraceptives**. The product which has been isolated is threonyl-prolyl-arginyl-lysine.

SUMM The **contraceptide** compounds of this invention are useful in mammalian species to control the development of pregnancies.

L15 ANSWER 12 OF 25 USPATFULL

ACCESSION NUMBER:	97:56710 USPATFULL
TITLE:	Ovulation control by regulating nitric oxide levels
INVENTOR(S):	Garfield, Robert E., Friendswood, TX, United States Yallampalli, Chandrasekhar, Houston, TX, United States
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5643944	19970701
APPLICATION INFO.:	US 1995-477189	19950607 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1993-165309, filed on 10 Dec 1993, now patented, Pat. No. US 5470847
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Criares, Theodore J.
LEGAL REPRESENTATIVE:	Arnold White & Durkee
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 13 OF 25 USPATFULL

ACCESSION NUMBER:	96:91979 USPATFULL
TITLE:	Use of human inhibin and human activin to increase the number of mature primate oocytes
INVENTOR(S):	Alak, Baha M., Beaverton, OR, United States Stouffer, Richard L., Aloha, OR, United States Wolf, Don P., Portland, OR, United States Woodruff, Teresa K., San Francisco, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation) Medical Research Foundation of Oregon, Beaverton, OR, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5563059	19961008
APPLICATION INFO.:	US 1993-21404	19930223 (8)

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Wityshyn, Michael G.
ASSISTANT EXAMINER:	Dadio, Susan M.
LEGAL REPRESENTATIVE:	Hasak, Janet E.
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	1379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 25 USPATFULL

ACCESSION NUMBER:	95:105837 USPATFULL
TITLE:	Ovulation control by regulating nitric oxide levels with arginine derivatives
INVENTOR(S):	Garfield, Robert E., Friendswood, TX, United States Yallampalli, Chandrasekhar, Houston, TX, United States

PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5470847	19951128	
APPLICATION INFO.:	US 1993-165309	19931210	(8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 616
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 25 USPATFULL

SUMM . . . be increased to stimulate ovulation using a nitric oxide source, alone or in combination with at least one of a **gonadotropin** and **clomiphene** or the like.

SUMM . . . acting on the above pathways. The best known agent which stimulates ovulation and is used for treatment of anovulation is **clomiphene** (MER 41). **Clomiphene** is a nonsteroidal antiestrogen that competes for estrogens at their binding sites. It is thought that **clomiphene** binds to estrogen receptors in the hypothalamus and blocks the negative feedback exerted by ovarian estrogens. The result is increased output of **gonadotropins** and stimulated follicle growth and maturation.

SUMM . . . a nitric oxide source such as L-arginine or a nitric oxide source in combination with at least one of a **gonadotropin** (LH/FSH agonist) and **clomiphene** or the like in amounts to stimulate ovulation. The amounts of **gonadotropins** (hCG, human chorionic **gonadotropin** or LH/FSH) or **gonadotropin** releasing hormones (GnRH) are equivalent to that needed to elevate LH levels to about 50 to 300 mIU/ml plasma. **Clomiphene** is used at doses of about 50 mg per day. Usually, treatment with the above agents is initiated on about. . .

DETD . . . hormone cascade and feedback mechanisms regulating ovulation. Therefore, nitric oxide sources may be particularly useful alone or in combination with **gonadotropins**, **clomiphene** or the like to stimulate ovulation. Furthermore, nitric oxide synthesis inhibitors alone or in combination with a progesterone, an estrogen,.

.

DETD . . . (e.g., L-arginine, sodium nitroprusside, nitroglycerin, isosorbide mononitrate and isosorbide dinitrate) alone or in combination with at least one of a **gonadotropin** (e.g., chorionic **gonadotropin**, hCG), **clomiphene** and LH-RH analogues (e.g., Lutrepulse.RTM., Lupron.RTM. and Nafarelin.RTM.) to stimulate ovulation.

DETD . . . to 10 g p.o./day

Sodium nitroprusside 0.2 to 1000 .mu.g/Kg/day

Nitroglycerin 0.1 to 10 mg

Isosorbide mononitrate 10-100 mg

Isosorbide dinitrate 10-100 mg

Human chorionic **gonadotropin** 1,000 to 20,000 USP units

Clomiphene 50 mg/day

Lutrepulse .RTM. (gonadorelin acetate) 0.5 to 5 mg/day

Lupron .RTM. (leuprolide acetate) 5-10 mg/day

Nafarelin .RTM. (nafarelin acetate) 200 to 800. . .

DETD Those agents may be administered in combination with one or more of a **gonadotropin**, **clomiphene** and an LH-RH analogue which stimulate the pituitary to secrete endogenous **gonadotropins** to activate the ovary. A **gonadotropin** may be chorionic **gonadotropin**, an LH-RH analogue may be Lutrepulse.RTM. (gonadorelin acetate), Lupron.RTM. (leuprolide acetate) or

Nafarelin.RTM. (nafarelin acetate).